Details

Autor(en) / Beteiligte

• Crous-Bou, Marta
• Du, Mengmeng
• Gunter, Marc J
• Setiawan, Veronica W
• Schouten, Leo J
• Shu, Xiao-ou
• Wentzensen, Nicolas
• Bertrand, Kimberly A
• Cook, Linda S
• Friedenreich, Christine M
• Gapstur, Susan M
• Goodman, Marc T
• Ibiebele, Torukiri I
• La Vecchia, Carlo
• Levi, Fabio
• Liao, Linda M
• Negri, Eva
• McCann, Susan E
• O’Connell, Kelly
• Palmer, Julie R
• Patel, Alpa V
• Ponte, Jeanette
• Reynolds, Peggy
• Sacerdote, Carlotta
• Sinha, Rashmi
• Spurdle, Amanda B
• Trabert, Britton
• van den Brandt, Piet A
• Webb, Penelope M
• Petruzella, Stacey
• Olson, Sara H
• De Vivo, Immaculata

Titel

Coffee consumption and risk of endometrial cancer: a pooled analysis of individual participant data in the Epidemiology of Endometrial Cancer Consortium (E2C2)

Ist Teil von

• The American journal of clinical nutrition, 2022-11, Vol.116 (5), p.1219-1228

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Epidemiologic studies suggest that coffee consumption may be inversely associated with risk of endometrial cancer (EC), the most common gynecological malignancy in developed countries. Furthermore, coffee consumption may lower circulating concentrations of estrogen and insulin, hormones implicated in endometrial carcinogenesis. Antioxidants and other chemopreventive compounds in coffee may have anticarcinogenic effects. Based on available meta-analyses, the World Cancer Research Fund (WCRF) concluded that consumption of coffee probably protects against EC. Our main aim was to examine the association between coffee consumption and EC risk by combining individual-level data in a pooled analysis. We also sought to evaluate potential effect modification by other risk factors for EC. We combined individual-level data from 19 epidemiologic studies (6 cohort, 13 case–control) of 12,159 EC cases and 27,479 controls from the Epidemiology of Endometrial Cancer Consortium (E2C2). Logistic regression was used to calculate ORs and their corresponding 95% CIs. All models were adjusted for potential confounders including age, race, BMI, smoking status, diabetes status, study design, and study site. Coffee drinkers had a lower risk of EC than non–coffee drinkers (multiadjusted OR: 0.87; 95% CI: 0.79, 0.95). There was a dose–response relation between higher coffee consumption and lower risk of EC: compared with non–coffee drinkers, the adjusted pooled ORs for those who drank 1, 2–3, and >4 cups/d were 0.90 (95% CI: 0.82, 1.00), 0.86 (95% CI: 0.78, 0.95), and 0.76 (95% CI: 0.66, 0.87), respectively (P-trend < 0.001). The inverse association between coffee consumption and EC risk was stronger in participants with BMI > 25 kg/m2. The results of the largest analysis to date pooling individual-level data further support the potentially beneficial health effects of coffee consumption in relation to EC, especially among females with higher BMI.